LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for ...

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is ...

https://www.tipranks.com/news/the-fly/rxsight-price-target-lowered-to-43-from-66-at-needham PureTech Health (PRTC) announced that the U.S. Food and Drug ...

PureTech Health said the Food and Drug Administration granted fast-track designation for a drug candidate to treat patients with acute myeloid leukemia. The biotherapeutics company said the ...

(RTTNews) - Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LYT-200, a first-in-class ...

PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, for the treatment ...

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is currently ...